Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019

被引：8
|
作者：
Kherabi, Yousra [1 ]
Frechet-Jachym, Mathilde [3 ]
Rioux, Christophe [1 ,4 ]
Yazdanpanah, Yazdan [1 ,2 ,4 ,5 ,6 ]
Mechai, Frederic [7 ,8 ]
Pourcher, Valerie [9 ]
Robert, Jerome [2 ,10 ]
Guglielmetti, Lorenzo [2 ,10 ]
机构：
[1] Hop Bichat Claude Bernard, Assistance Publ Hop Paris, Paris, France
[2] Sorbonne Univ, INSERM, U1135, Paris, France
[3] Ctr Hosp Bligny, Briis Sous Forges, France
[4] Assistance Publ Hop Paris, Paris, France
[5] Univ Paris, INSERM, IAME, Paris, France
[6] Univ Paris Diderot, Paris, France
[7] Hop Avicenne, Assistance Publ Hop Paris, Paris, France
[8] Hop Avicenne, Bobigny, France
[9] Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Paris, France
[10] Sorbonne Univ, Hop Pitie Salpetriere, Assistance Publ Hop Paris, Paris, France
来源：
EMERGING INFECTIOUS DISEASES | 2022年 / 28卷 / 09期
关键词：
CULTURE CONVERSION; XDR-TB; FLUOROQUINOLONES; TOLERABILITY; SAFETY; IMPACT;
D O I：
10.3201/eid2809.220458
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre-XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France. The study included 298 patients treated for MDR TB at 3 reference centers during 2006-2019. Of those, 205 (68.8%) cases were fluoroquinolone-susceptible MDR TB and 93 (31.2%) were preXDR/XDR TB. Compared with fluoroquinolone-susceptible MDR TB, pre-XDR/XDR TB was associated with more cavitary lung lesions and bilateral disease and required longer treatment. Overall, 202 patients (67.8%) had favorable treatment outcomes, with no significant difference between pre-XDR/XDR TB (67.7%) and fluoroquinolone-susceptible MDR TB (67.8%; p = 0.99). Pre-XDR/XDR TB was not associated with higher risk for serious adverse events.
引用
收藏
页码：1796 / 1804
页数：9
相关论文
共 50 条
  • [1] Revised Definitions of Multidrug-Resistant Tuberculosis Treatment Outcomes: Closer to the Reality?
    Bastard, Mathieu
    Bonnet, Maryline
    du Cros, Philipp
    Khamraev, Atadjan Karimovich
    Hayrapetyan, Armen
    Kimenye, Kamene
    Khurkhumal, Shazina
    Dlamini, Themba
    Telnov, Alex
    Sanchez-Padilla, Elisabeth
    Hewison, Cathy
    Varaine, Francis
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (03) : 355 - 358
  • [2] Treatment Patterns and Outcomes in a Nationwide Cohort of Older and Younger Veterans with Waldenstrom Macroglobulinemia, 2006-2019
    Chien, Hsu-Chih
    Morreall, Deborah
    Patil, Vikas
    Rasmussen, Kelli M.
    Yong, Christina
    Li, Chunyang
    Passey, Deborah G.
    Burningham, Zachary
    Sauer, Brian C.
    Halwani, Ahmad S.
    CANCERS, 2021, 13 (07)
  • [3] Real-world treatment patterns and outcomes in a national study of veterans with Waldenstrom macroglobulinemia, 2006-2019
    Chien, Hsu-Chih
    Morreall, Deborah
    Patil, Vikas
    Rasmussen, Kelli M.
    Yong, Christina M.
    Li, Chun-Yang
    Passey, Deborah G.
    Burningham, Zachary
    Sauer, Brian C.
    Halwani, Ahmad S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : E184 - E187
  • [4] Pregnancy and Infant Outcomes After Prenatal Exposure to Golimumab in Denmark, Finland, and Sweden 2006-2019
    Karlsson, Paer
    Gembert, Karin
    Esslinger, Suzan
    Geldhof, Anja
    Gissler, Mika
    Leinonen, Maarit K.
    Otero-Lobato, Marijo
    Pedersen, Lars
    Cesta, Carolyn E.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (08)
  • [5] Adolescent pregnancies between 2006-2019: Temporal trends, risk factors and adverse pregnancy outcomes
    Richley, Michael
    Han, Christina S.
    Wisk, Lauren E.
    Moin, Tannaz
    Copeland, Timothy
    Everett, Estelle
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2024, 230 (01) : S169 - S170
  • [6] Tuberculosis under anti-TNF therapy: case series of a center (reporting the experience from the period 2006-2019)
    Valido, A.
    Silva-Dinis, J.
    Fonseca, J. E.
    ACTA REUMATOLOGICA PORTUGUESA, 2020, 45 (04): : 281 - 287
  • [7] Tuberculosis treatment outcomes among precarious patients in France
    Mechai, F.
    Bachelet, D.
    Han, L.
    Dubert, M.
    Parisey, M.
    Cordel, H.
    Bourgarit, A.
    Bertrac, C.
    Chauveau, S.
    Billard-Pomares, T.
    Carbonnelle, E.
    Bouchaud, O.
    Yazdanpanah, Y.
    Vignier, N.
    Laouenan, C.
    INFECTIOUS DISEASES NOW, 2022, 52 (07): : 389 - 395
  • [8] Outcomes and complications of anal sacculectomy for non-neoplastic anal sac disease in cats: 8 cases (2006-2019)
    Sandoval, J. C. Jimeno
    Charlesworth, T.
    Anderson, D.
    JOURNAL OF SMALL ANIMAL PRACTICE, 2022, 63 (01) : 56 - 61
  • [9] REPORTING OF PATIENT-REPORTED OUTCOMES FOR PSORIASIS IN FDA DRUG LABELS, MEDICAL REVIEWS, AND TRIAL PUBLICATIONS: 2006-2019
    Hong, K.
    Seo, S.
    VALUE IN HEALTH, 2021, 24 : S93 - S93
  • [10] Treatment outcomes of various types of tuberculosis in Pakistan, 2006 and 2007
    Chughtai, A. A.
    Maclntyre, C. R.
    Wang, Y. A.
    Gao, Z.
    Khan, W.
    EASTERN MEDITERRANEAN HEALTH JOURNAL, 2013, 19 (06) : 535 - 541
12345